Seattle Genetics Inc (SGEN)

SGEN (NASDAQ:Drugs) EQUITY
$47.50
pos +1.30
+2.81%
Today's Range: 46.46 - 47.58 | SGEN Avg Daily Volume: 1,186,400
Last Update: 08/22/17 - 4:00 PM EDT
Volume: 633,370
YTD Performance: -12.45%
Open: $46.46
Previous Close: $46.20
52 Week Range: $26.02 - $50.67
Oustanding Shares: 143,027,210
Market Cap: 6,622,159,823
6-Month Chart
TheStreet Ratings Grade for SGEN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 3 3 3
Moderate Buy 2 2 2 2
Hold 7 7 7 7
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 2.42 2.42 2.42 2.42
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -32.15
Price Earnings Comparisons:
SGEN Sector Avg. S&P 500
-32.15 0.00 35.60
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-30.63% 1.81% 8.71%
GROWTH 12 Mo 3 Yr CAGR
Revenue 24.20 0.60 0.16
Net Income 0.00 1.20 0.00
EPS 0.00 1.00 0.00
Earnings for SGEN:
EBITDA -0.12B
Revenue 0.42B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $-0.42 $-0.43 $-1.67 $-1.31
Number of Analysts 8 7 10 9
High Estimate $-0.31 $-0.36 $-1.52 $-0.28
Low Estimate $-0.47 $-0.51 $-1.79 $-1.86
Prior Year $-0.23 $-0.39 $-1.00 $-1.67
Growth Rate (Year over Year) -80.98% -10.99% -67.00% 21.49%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Bearish
Dec 12, 2016 | 7:45 AM EST
SGEN was downgraded from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $70 price target.
Bullish
Sep 15, 2016 | 7:08 AM EDT
SGEN was upgraded from Sell to Neutral, Goldman Sachs said. $47 price target. Expect greater market penetration for Adcetris.
Bearish
Jul 27, 2016 | 7:28 AM EDT
SGEN was downgraded to Hold, Cantor Fitzgerald said. Buy rating, based on a $43 price target.
Selling in SGEN has created a huge upside vacuum; take advantage with this vertical call spread strategy.
Bullish
Feb 10, 2016 | 7:36 AM EST
SGEN was upgraded to Buy, Cantor Fitzgerald said. $38 price target. Guidance for Adcetris is likely too conservative.
This biotech is not as high-risk a play as you might think.  
The trade is once again the out-of-the-money, bullishly biased vertical call spread.
Bullish
Oct 31, 2014 | 7:01 AM EDT
SGEN was upgraded from Sell to Hold, Cantor Fitzgerald said. $35 price target. Company has improved pipeline visibility. 
Bearish
Sep 30, 2014 | 7:42 AM EDT
SGEN was downgraded form Neutral to Underperform, Bank of America/Merrill Lynch said. $34 price target. Aethera data was not as positiv...
A HERO may still emerge.

Columnist Conversations

today is a good day to lighten the load and take some positions off the table. SOLD WB OCT 85 CALL AT 11 (i...
I reached out last week to my close friend Ken Shreve, who is a prominent writer for the IBD.  I asked Ke...
I reached out last week to my close friend Ken Shreve, who is a prominent writer for the IBD.  I asked Ke...
View Chart »  View in New Window »

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.